


FOCUS ON ADVANCING TREATMENT FOR ACUTE MYELOID LEUKEMIA

References

1. National Comprehensive Cancer Network. Acute Myeloid Leukemia (version 1.2018). https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. Accessed July 23, 2018.
2. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*. 2017;129(4):424-447.
3. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. *J Clin Oncol*. 2018;JCO2017776112.
4. Lim WS, Tardi PG, Dos Santos N, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. *Leuk Res*. 2010;34(9):1214-1223.
5. Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. *Leuk Res*. 2009;33(1):129-139.
6. Feldman EJ, Kolitz JE, Trang JM, et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. *Leuk Res*. 2012;36(10):1283-1289.
7. Kolitz JE, Strickland SA, Cortes JE, Hogge D, Lancet JE, Goldberg SL. Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML). *J Clin Oncol*. 2017;35(15 (Suppl)):7036.
8. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. *Blood*. 2002;100(5):1532-1542.
9. Carow CE, Levenstein M, Kaufmann SH, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. *Blood*. 1996;87(3):1089-1096.
10. Assi R, Ravandi F. FLT3 inhibitors in acute myeloid leukemia: Choosing the best when the optimal does not exist. *Am J Hematol*. 2018;93(4):553-563.
11. Mrozek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. *J Clin Oncol*. 2012;30(36):4515-4523.
12. Stone RM, Dohner H, Ehninger G, et al. CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML. *J Clin Oncol*. 2011;29(suppl):TPS199-TPS199.
13. Döhner K, Thiede C, Larson RA, et al. Prognostic impact of *NPM1/FLT3-ITD* genotypes from randomized patients with acute myeloid leukemia (AML) treated within the International Ratify Study. *Blood*. 2017;130:467-467.
14. Lee LY, Hernandez D, Rajkhowa T, et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. *Blood*. 2017;129(2):257-260.
15. Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. *Lancet Oncol*. 2017;18(8):1061-1075.





FOCUS ON ADVANCING TREATMENT FOR ACUTE MYELOID LEUKEMIA

16. FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation [press release]. November 28, 2018.
17. Cortes J, Khaled S, Martinelli G. Efficacy and safety of single-agent quizartinib, a potent and selective FLT3 inhibitor, in patients with FLT3-internal tandem duplication–mutated relapsed/refractory acute myeloid leukemia (AML) enrolled in the global, phase III, randomized controlled Quantum-R Trial. Paper presented at: American Society of Hematology Annual Meeting; December 4-8, 2018; San Diego.
18. Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R. Isocitrate dehydrogenase mutations in myeloid malignancies. *Leukemia*. 2017;31(2):272-281.
19. Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. *N Engl J Med*. 2015;373(12):1136-1152.
20. Santos FP, Jones D, Qiao W, et al. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. *Cancer*. 2011;117(10):2145-2155.
21. Stein EM, DiNardo C, Altman JK, et al. Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: results of a phase 1/2 trial. *Blood*. 2015;126:323-323.
22. Green CL, Evans CM, Zhao L, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. *Blood*. 2011;118(2):409-412.
23. DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in *IDH1*-mutated relapsed or refractory AML. *N Engl J Med*. 2018;378(25):2386-2398.
24. Medinger M, Lengerke C, Passweg J. Novel prognostic and therapeutic mutations in acute myeloid leukemia. *Cancer Genomics Proteomics*. 2016;13(5):317-329.
25. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. *Cancer Discov*. 2016;6(10):1106-1117.
26. Roberts AW, Huang D. Targeting BCL2 with BH3 mimetics: Basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies. *Clin Pharmacol Ther*. 2017;101(1):89-98.
27. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naïve, elderly patients with acute myeloid leukemia. *Blood*. 2019;133(1):7-17.
28. Wei A, Strickland SA, Roboz GJ, et al. Safety and efficacy of venetoclax plus low-dose cytarabine in treatment-naïve patients aged ≥65 years with acute myeloid leukemia. *Blood*. 2016;128:102-102.
29. Krupka C, Kufer P, Kischel R, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. *Blood*. 2014;123(3):356-365.
30. Buckley SA, Walter RB. Antigen-specific immunotherapies for acute myeloid leukemia. *Hematology Am Soc Hematol Educ Program*. 2015;2015:584-595.
31. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. *Lancet Oncol*. 2014;15(9):986-996.
32. Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. *Lancet*. 2012;379(9825):1508-1516.





33. Ravandi F, Stein AS, Kantarjian H, Walter RB, Subklewe M. A phase 1 first-in-human study of AMG 330, an anti-CD33 bispecific T-cell engager (BiTE®) antibody construct, in relapsed/refractory acute myeloid leukemia (R/R AML). Paper presented at: American Society of Hematology Annual Meeting; December 1-4, 2018; San Diego.
34. Hoseini SS, Cheung NK. Acute myeloid leukemia targets for bispecific antibodies. *Blood Cancer J.* 2017;7(4):e552.
35. Vergez F, Green AS, Tamburini J, et al. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. *Haematologica.* 2011;96(12):1792-1798.
36. Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045 [press release]. February 20, 2019.
37. Uy GL, Godwin J, Rettig MP, et al. Preliminary results of a phase 1 study of flotetuzumab, a CD123 x CD3 bispecific Dart® protein, in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. *Blood.* 2017;130:637-637.

